SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Alan Cole who wrote (3247)6/8/1999 8:52:00 AM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 10280
 
Thanks Alan,

I really appreciate filling me in on The Medical Letter.

I understand presenting things conservatively.

But, in time we will see that S-albuterol by inducing calcium in the smooth muscle tissue of the lung causes the reduced FEV1 that is observed with racemic albuterol use. It is already evident in the literature. MD's are observing the reduced FEV1 and patients are reporting favorable responses to levalbuterol. It all fits, at least to this simpleton.

In time the prestigious Medical Letter will catch on. <g>

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News